logo
Stocks to watch next week: CoreWeave, Cisco, Aviva, Entain and Persimmon

Stocks to watch next week: CoreWeave, Cisco, Aviva, Entain and Persimmon

Yahoo2 days ago
Earnings season is slowing down but next week several key companies are still set to release earnings, giving markets some insight into their performance and future prospects.
In the US, AI infrastructure CoreWeave (CRWV) will tell markets on Tuesday how its $9bn all-stock acquisition of Core Scientific is going along, following resistance from Core Scientific's shareholders due to CoreWeave's stock price decline since the merger announcement.
Markets are optimistic about Cisco (CSCO), who is set to report fiscal fourth-quarter earnings of $0.98 per share on $14.63bn in revenue. The company has consistently surpassed Wall Street estimates so we'll find out Wednesday if it's the case once again.
In the UK, insurer Aviva (AV.L) will release its first results since acquiring Direct Line in a £6bn deal, with analysts divided on the short-term outlook.
Also in the UK but with a US reach, Entain (ENT.L) the owner of Ladbrokes and Coral will report its interim result on Tuesday. Markets will want to hear more about the performance of its US joint venture, BetMGM.
Persimmon (PSN.L), one of the UK's largest housebuilders, will on Wednesday offer a telling glimpse into the state of its own business, the housing market, and the broader UK economy.
Here's more on what to look out for:
CoreWeave (CRWV) - Reports second-quarter earnings on Tuesday 12 August
CoreWeave, the New Jersey-based AI infrastructure firm with a market capitalisation of roughly $59bn, is set to report its second-quarter earnings, with analysts predicting a loss of $0.21 per share on revenues of $1.08bn. The Zacks Consensus Estimate, which has remained unchanged for the past 60 days, puts the anticipated loss at 23 cents per share, while total revenue is projected to reach $1.08bn.
This will mark CoreWeave's (CRWV) second earnings release since it began trading publicly on March 28, 2025. The company, which focuses on providing scalable cloud infrastructure to support and accelerate generative AI has emerged as a key player in the AI data centre market.
In addition to its financial results, analysts are particularly interested in the company's ongoing $9bn all-stock deal to acquire Core Scientific (CORZ), a data centre landlord that provides computing power to major tech players such as Microsoft (MSFT) and OpenAI. The merger, announced in July, was seen by many on Wall Street as a strategic move to reduce costs for CoreWeave (CRWV) by eliminating roughly $10bn in lease obligations. Core Scientific, which operates AI data centres across the US, leases out its computing power to these tech giants.
Read more: UK taxpayers 'subsidising' S&P 500, says LSEG boss
However, the deal has been met with resistance from some of Core Scientific's top shareholders. According to sources familiar with the matter, a number of these investors are preparing to vote against the merger unless the terms are adjusted. The core issue lies in the fixed ratio of 0.1235 newly issued CoreWeave (CRWV) shares offered to Core Scientific (CORZ) shareholders. This arrangement does not offer any protection if CoreWeave's stock price declines, which it has done significantly since the merger was first announced.
CoreWeave's stock has dropped by around 30% since the deal was made public on July 7, causing Core Scientific's valuation in the acquisition to fall from approximately $20.25 per share to just over $13 per share. This sharp decline in value has left Core Scientific shareholders concerned about the fairness of the deal, with many now fearing they will be left short-changed.
Cisco (CSCO) – reports fiscal fourth-quarter results on Wednesday 13 August
Cisco, the $270bn California-based networking giant, is set to release its results amid a quietly growing wall of optimism. Deutsche Bank (DB) recently highlighted 'improved visibility towards durable mid-single-digit growth in upcoming years', noting tailwinds from AI infrastructure, enterprise deployments and sovereign spending.
Cisco (CSCO) develops, manufactures and sells networking hardware, software, telecommunications equipment.
According to Koyfin consensus data, the market expects Cisco (CSCO) to report $0.98 in earnings per share (EPS) on $14.63bn in revenue, reflecting year-on-year growth of approximately 13% and 7%, respectively. The company has beaten Wall Street estimates for 11 consecutive quarters. Full-year 2025 revenue and EPS are forecasted to reach $56.62bn and $3.79, respectively, with mid-single-digit growth expected in fiscal 2026.
JPMorgan analysts have maintained their overweight rating on Cisco (CSCO), with a price target of $73.00. They cited anticipated revenue growth driven by the ongoing Campus upgrade cycle and the launch of the next-generation Catalyst-2026 switch series. This new product is expected to boost revenue by increasing both the average selling price and adoption rate.
Aviva (AV.L) – reports half-year results on Thursday 14 August
Insurer Aviva (AV.L) is set to release its first set of results since completing its takeover of Direct Line, following rival Legal & General's (LGEN.L) earnings a week earlier. The market is eager to see how the £6bn acquisition will impact Aviva's financials, with analysts divided on the near-term outlook.
Morgan Stanley analysts believe Aviva (AV.L) could exceed consensus forecasts, citing strong potential from the integration of Direct Line. However, UBS (UBS) analysts suggest investors will need to be patient, as a more detailed update on the integration won't come until later in the year. The insurer's management has targeted £125m in cost savings from the acquisition, a goal shared prior to the deal's completion.
In the meantime, dividends are expected to continue growing, with a yield forecast of 6.04% for 2025 and 6.48% for 2026. As of now, 10 out of 14 analysts rate the stock as a Buy or Strong Buy, reflecting optimism about the company's future.
Read more: What are share buybacks?
In Aviva's most recent full-year results, published on 27 February, operating profit rose 20% to £1.77bn, while the dividend climbed 7% to 35.7p a share. Looking ahead, the insurer is targeting £2bn of operating profit by 2026. General insurance premiums and assets under management also showed robust growth.
Entain (ENT.L) – Reports interim 2025 results on Tuesday, 12 August
Entain (ENT.L), the owner of Ladbrokes and Coral, has seen its shares soar more than 40% since the beginning of the year, with some analysts predicting the strong momentum could continue. A key driver behind this surge has been the impressive performance of its US joint venture, BetMGM, which has turned profitable and continues to show robust growth.
In a recent second-quarter update, Entain (ENT.L) revealed that BetMGM is expected to generate net revenue of at least $2.7bn and EBITDA of at least $150m for the year. The company has lifted its annual guidance for BetMGM, thanks to ongoing strong online growth in the US.
For 2025, Entain (ENT.L) forecasts that BetMGM's net revenues will total at least $2.6bn, up from an earlier forecast of $2.4bn to $2.5bn. The company credited this upgrade to higher punter bets in internet gaming and online sports, noting that trading has been 'broadly consistent' with the 34% jump in net revenues achieved during the first quarter.
BetMGM, a joint venture between Entain and MGM Resorts, has been a growth engine for the FTSE 100 (^FTSE) bookmaker. Entain also expects BetMGM to deliver a minimum of $100m in earnings before interest, taxes, depreciation, and amortisation (EBITDA), an improvement from prior predictions that it would just be positive.
For the wider business, analysts at Citi (C) expect modest revenue growth in both the full year and into 2026, with earnings per share forecast to rise by just over 2% in each of the next two years.
Persimmon (PSN.L) – reports first-half results on Wednesday 13 August
Persimmon (PSN.L), one of the UK's largest housebuilders, has seen its shares drop by more than 25% over the past year, despite broader market gains. Rising input costs, sluggish interest rate cuts, and housing affordability issues continue to weigh on the company, alongside the ongoing burden of fire safety and cladding remediation costs.
'Persimmon's shares have crumbled over the past year. They have fallen by more than a quarter, despite healthy gains from the headline indices. Input cost inflation remains an issue, as does housing affordability as interest rates come down only slowly, while the industry remains dogged by costs for fire safety and cladding remediation on historic projects. Taylor Wimpey (TW.L) has become the latest builder to set aside further provisions here," Russ Mould, AJ Bell investment director, Danni Hewson, AJ Bell head of financial analysis and Dan Coatsworth, AJ Bell investment analyst, wrote.
The company has already set aside £275m for fire safety provisions, but investors are closely watching key metrics like its £1.1bn order book.
Looking ahead, Persimmon has forecast between 11,000 and 11,500 completions this year, up from 10,664 in 2023. Analysts expect an operating profit of £447m, a 21% increase, largely due to a 4% rise in sales and the absence of last year's £36m in exceptional charges.
With £259m in net cash as of December, analysts predict a small increase in Persimmon's dividend for 2025, from 60p to 62p per share.
Other companies reporting next week include:
Monday 11 August
AST SpaceMobile (ASTS)
Barrick Mining (B)
AMC (AMC)
Hypoport (0JVS.IL)
ING Group (ING)
Marshalls (MSLH.L)
Plus500 (PLUS.L)
Salzgitter (SZG.MU)
Tuesday 12 August
Derwent London (DLN.L)
Sea Limited (SEAMECLTD.NS)
Spirax (SPX.L)
Wednesday 13 August
Balfour Beatty (BBY.L)
Beazley (BEZ.L)
Hill & Smith (HILS.L)
Thursday 14 August
Admiral (ADM.L)
Antofagasta (ANTO.L)
Applied Materials (AMAT)
Deere & Co (DE)
JD.com (JD)
NetEase (NTES)
Nu (NU)
Friday 15 August
Flowers Foods (FLO)
You can read Yahoo Finance's full calendar here.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?

Yahoo

time7 minutes ago

  • Yahoo

Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?

Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills? was originally published by The Motley Fool 登入存取你的投資組合

TBC Bank Group Second Quarter 2025 Earnings: EPS: GEL6.14 (vs GEL5.94 in 2Q 2024)
TBC Bank Group Second Quarter 2025 Earnings: EPS: GEL6.14 (vs GEL5.94 in 2Q 2024)

Yahoo

time7 minutes ago

  • Yahoo

TBC Bank Group Second Quarter 2025 Earnings: EPS: GEL6.14 (vs GEL5.94 in 2Q 2024)

Explore TBC Bank Group's Fair Values from the Community and select yours TBC Bank Group (LON:TBCG) Second Quarter 2025 Results Key Financial Results Revenue: GEL719.5m (up 11% from 2Q 2024). Net income: GEL340.9m (up 5.0% from 2Q 2024). Profit margin: 47% (down from 50% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: GEL6.14 (up from GEL5.94 in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period TBC Bank Group Earnings Insights Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Banks industry in the United Kingdom. Performance of the British Banks industry. The company's shares are up 1.5% from a week ago. Balance Sheet Analysis While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on TBC Bank Group's balance sheet. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ArcelorMittal (AMS:MT) Strong Profits May Be Masking Some Underlying Issues
ArcelorMittal (AMS:MT) Strong Profits May Be Masking Some Underlying Issues

Yahoo

time7 minutes ago

  • Yahoo

ArcelorMittal (AMS:MT) Strong Profits May Be Masking Some Underlying Issues

Explore ArcelorMittal's Fair Values from the Community and select yours The market shrugged off ArcelorMittal S.A.'s (AMS:MT) solid earnings report. We think that investors might be worried about some concerning underlying factors. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. How Do Unusual Items Influence Profit? For anyone who wants to understand ArcelorMittal's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from US$1.5b worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. ArcelorMittal had a rather significant contribution from unusual items relative to its profit to June 2025. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Our Take On ArcelorMittal's Profit Performance As previously mentioned, ArcelorMittal's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that ArcelorMittal's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. In terms of investment risks, we've identified 1 warning sign with ArcelorMittal, and understanding it should be part of your investment process. Today we've zoomed in on a single data point to better understand the nature of ArcelorMittal's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store